INADEQUACY OF COMBINED 5-FLUOROURACIL, VERY-HIGH-DOSE LEUCOVORIN, MITOMYCIN-C AND CISPLATIN AS 2ND-LINE THERAPY FOR ADVANCED COLON-CANCER

  • Authors:
    • G NASTASI
    • C PORTA
    • M MORONI
    • S RISO
    • G SESANA
  • View Affiliations

  • Published online on: September 1, 1995     https://doi.org/10.3892/or.2.5.815
  • Pages: 815-818
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fourteen patients with metastatic colon cancer which had progressed under fluoro-folates chemotherapy were treated with MM-C (10 mg/m(2) on day 1), 5-FU (370 mg/m(2) for 5 consecutive days), l-LV (500 mg/m(2) for 5 consecutive days) and CDDP (70 mg/m(2) on day 4), every 29th day till further disease progression. Neither CR nor PR were observed; 3 patients only had stable disease, while the extant 11 patients progressed. Resulting toxicity was severe. Since no antitumor effects were evidenced in the first 14 patients, the study was discontinued according to commonly accepted criteria.

Related Articles

Journal Cover

September 1995
Volume 2 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
NASTASI G, PORTA C, MORONI M, RISO S and SESANA G: INADEQUACY OF COMBINED 5-FLUOROURACIL, VERY-HIGH-DOSE LEUCOVORIN, MITOMYCIN-C AND CISPLATIN AS 2ND-LINE THERAPY FOR ADVANCED COLON-CANCER. Oncol Rep 2: 815-818, 1995
APA
NASTASI, G., PORTA, C., MORONI, M., RISO, S., & SESANA, G. (1995). INADEQUACY OF COMBINED 5-FLUOROURACIL, VERY-HIGH-DOSE LEUCOVORIN, MITOMYCIN-C AND CISPLATIN AS 2ND-LINE THERAPY FOR ADVANCED COLON-CANCER. Oncology Reports, 2, 815-818. https://doi.org/10.3892/or.2.5.815
MLA
NASTASI, G., PORTA, C., MORONI, M., RISO, S., SESANA, G."INADEQUACY OF COMBINED 5-FLUOROURACIL, VERY-HIGH-DOSE LEUCOVORIN, MITOMYCIN-C AND CISPLATIN AS 2ND-LINE THERAPY FOR ADVANCED COLON-CANCER". Oncology Reports 2.5 (1995): 815-818.
Chicago
NASTASI, G., PORTA, C., MORONI, M., RISO, S., SESANA, G."INADEQUACY OF COMBINED 5-FLUOROURACIL, VERY-HIGH-DOSE LEUCOVORIN, MITOMYCIN-C AND CISPLATIN AS 2ND-LINE THERAPY FOR ADVANCED COLON-CANCER". Oncology Reports 2, no. 5 (1995): 815-818. https://doi.org/10.3892/or.2.5.815